Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 24, Pages 9849-9860Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm401649j
Keywords
-
Categories
Funding
- Brazilian CAPES [8792127]
- Ligue Nationale Contre le Cancer
- Momentum Grant
- CNRS
- Universite Lyon 1 [UMR 5086]
- Ligue Nationale Contre le Cancer (Equipe labellisee Ligue)
- Region Rhone-Alpes (CIBLE)
- French ANR
- Hungarian NIH [2010-INT-1101-01]
Ask authors/readers for more resources
We recently identified a chromone derivative, 5-(4-bromobenzyloxy)-2-(2-(5-methoxyindolypethyl-1-carbonyl)-4H-chromen-4-one, named here as chromone 1, as a potent, selective, nontoxic, and nontransported inhibitor of ABCG2-mediated drug efflux (Valdameri et al. J. Med. Chem. 2012, 55, 966). We have now synthesized a series of 14 derivatives to study the structure activity relationships controlling both drug efflux and ATPase activity of ABCG2 and to elucidate their molecular mechanism of interaction and inhibition. It was found that the 4-bromobenzyloxy substituent at position 5 and the methoxyindole are important for both inhibition of mitoxantrone efflux and inhibition of basal ATPase activity. Quite interestingly, methylation of the central amide nitrogen strongly altered the high affinity for ABCG2 and the complete inhibition of mitoxantrone efflux and coupled ATPase activity. These results allowed the identification of a critical central inhibitory moiety of chromones that has never been, investigated previously in any series of inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available